Guggenheim analyst Yatin Suneja raised the firm’s price target on Prometheus to $225 from $185 and keeps a Buy rating on the shares after having attended the ECCO conference in Copenhagen and hosted an investor dinner to discuss Phase II updates for PRA023 in ulcerative colitis and Crohn’s Disease. The firm, which tells investors that the data updates build on "the first-in-class/best-in-class profile" for PRA023, thinks that if replicated in Phase 3, ‘023 could be favorably positioned not only for CDx-positive population but for the general population, which would unlock "a huge market opportunity."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RXDX:
- TipRanks ‘Perfect 10’ List: These 2 Healthcare Stocks Look Compelling at Current Levels
- RXDX vs. IONS: Which Biotech Stock is Better?
- Prometheus price target raised to $138 from $114 at Piper Sandler
- Prometheus price target raised to $150 from $125 at Oppenheimer
- Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress